Krystal Biotech

KRYSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$9.663 B

$326.45 +1.17%

Close of 7 Aug 2026

Revenue

$389.1M

#2039 by revenue

Earnings

$204.8M

#1001 by earnings

Shares outstanding

29,598,836

Latest filing cover page

P/E ratio

47.2

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#11Bio-TechneTECH$11.3B
#12Apogee TherapeuticsAPGE$10.2B
#13Krystal BiotechKRYS$9.66B
#14RepligenRGEN$9.25B
#15Kymera TherapeuticsKYMR$8.94B

Where these numbers come from

Share counts and financials for Krystal Biotech are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.